Innoviva, Inc. (THRX)
Feb 14, 2024 - THRX was delisted (reason: acquired by Concentra Biosciences)
4.060
0.00 (0.00%)
Inactive · Last trade price on Feb 13, 2024
Theseus Pharmaceuticals Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Theseus Pharmaceuticals stock had an average target of 11.75, with a low estimate of 7.00 and a high estimate of 24.
Price Target: $11.75 (+189.41%)
Analyst Consensus: Strong Buy
No price target forecast data available
* Price targets were last updated on Jul 14, 2023.
Analyst Ratings
The average analyst rating for Theseus Pharmaceuticals stock from 5 stock analysts was "Strong Buy". This means that analysts believed this stock was likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '23 | Oct '23 | Nov '23 | Dec '23 | Jan '24 | Feb '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $23 → $7 | Buy | Maintains | $23 → $7 | +72.41% | Jul 14, 2023 |
| Wedbush | Wedbush | Buy Maintains $24 → $7 | Buy | Maintains | $24 → $7 | +72.41% | Jul 14, 2023 |
| Needham | Needham | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Jul 14, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $22 → $9 | Strong Buy | Maintains | $22 → $9 | +121.67% | Jul 14, 2023 |
| Needham | Needham | Strong Buy Reiterates $23 | Strong Buy | Reiterates | $23 | +466.50% | May 26, 2023 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.31
from -1.31
EPS Next Year
-0.96
from -1.31
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||
| Avg | n/a | n/a | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|
| High | -1.34 | -0.99 | ||||
| Avg | -1.31 | -0.96 | ||||
| Low | -1.25 | -0.92 |
EPS Growth
| EPS Growth | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.